Daily phosphodiesterase type 5 inhibitor therapy: a new treatment option for prostatitis/prostatodynia?

被引：6
|
作者：
Kirby, Roger S. [1 ]
Carson, Culley, III [3 ]
Dasgupta, Prokar [1 ,2 ]
机构：
[1] Kings Coll London, Guys Hosp, Prostate Ctr, London WC2R 2LS, England
[2] Kings Coll London, Guys Hosp, Dept Urol, London WC2R 2LS, England
[3] Univ N Carolina, Dept Urol, Chapel Hill, NC USA
来源：
BJU INTERNATIONAL | 2014年 / 113卷 / 05期
关键词：
treatment for prostatitis; tadalafil; 5; mg; pelvic pain; prostatitis; ERECTILE DYSFUNCTION; TADALAFIL; PROSTATITIS; MECHANISM; SYMPTOMS; LUTS; BPH;
D O I：
10.1111/bju.12681
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：694 / 695
页数：2
相关论文
共 50 条
  • [21] Phosphodiesterase Type 5 Inhibitors as Adjunctive Therapy in the Management of Systolic Heart Failure
    Cvelich, Ramonna G.
    Roberts, Sarah C.
    Brown, Jamie N.
    ANNALS OF PHARMACOTHERAPY, 2011, 45 (12) : 1551 - 1558
  • [22] Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model
    Wang, Rong
    Chen, Wenli
    Zhang, Qiang
    Liu, Yong
    Qiao, Xiaoyun
    Meng, Kui
    Mao, Ying
    JOURNAL OF NEURO-ONCOLOGY, 2015, 122 (01) : 35 - 42
  • [23] Phosphodiesterase type 5 inhibitor Tadalafil increases Rituximab treatment efficacy in a mouse brain lymphoma model
    Rong Wang
    Wenli Chen
    Qiang Zhang
    Yong Liu
    Xiaoyun Qiao
    Kui Meng
    Ying Mao
    Journal of Neuro-Oncology, 2015, 122 : 35 - 42
  • [24] Effect of the phosphodiesterase type 5 inhibitor tadalafil on pulmonary hemodynamics in a canine model of pulmonary hypertension
    Hori, Yasutomo
    Kondo, Chigusa
    Matsui, Maho
    Yamagishi, Maki
    Okano, Shozo
    Chikazawa, Seishiro
    Kanai, Kazutaka
    Hoshi, Fumio
    Itoh, Naoyuki
    VETERINARY JOURNAL, 2014, 202 (02) : 334 - 339
  • [25] Improvement of cognitive dysfunction by a novel phosphodiesterase type 5 inhibitor, Tadalafil
    Otari, Kishor Vasant
    Patil, Rupesh J.
    Upasani, Chandrashekhar Devidas
    FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (02) : 263 - 274
  • [26] Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus
    M A Vickers
    R Satyanarayana
    International Journal of Impotence Research, 2002, 14 : 466 - 471
  • [27] Selective phosphodiesterase type 5 inhibition using tadalafil for the treatment of erectile dysfunction
    Kuan, J
    Brock, G
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2002, 11 (11) : 1605 - 1613
  • [28] 2009 Update on Phosphodiesterase Type 5 Inhibitor Therapy Part 2: Updates on Optimal Utilization for Sexual Concerns and Rare Toxicities in This Class (CME)
    Shindel, Alan W.
    JOURNAL OF SEXUAL MEDICINE, 2009, 6 (09) : 2352 - 2364
  • [29] Phosphodiesterase type 5 inhibitors for the treatment of erectile dysfunction in patients with diabetes mellitus
    Vickers, MA
    Satyanarayana, R
    INTERNATIONAL JOURNAL OF IMPOTENCE RESEARCH, 2002, 14 (06) : 466 - 471
  • [30] PHOSPHODIESTERASE TYPE-5 INHIBITOR AND OXIDATIVE STRESS
    Speranza, L.
    Franceschelli, S.
    Pesce, M.
    Vinciguerra, I.
    De Lutiis, M. A.
    Grilli, A.
    Felaco, M.
    Patruno, A.
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2008, 21 (04) : 879 - 889
12345